Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
Samuele Massarut, Ingrid Potyka, Christobel Saunders, Gloria Petralia, Marcelle Bernstein, Norman R. Williams, Steinar Lundgren, Konstantin J. Dedes, Tammy Corica, Magali Le Blanc-Onfroy, Mary Falzon, Frederik Wenz, W. Eiermann, Fernando Bozza, David Joseph, Marc Sütterlin, Dennis R. Holmes, Montserrat Pazos, Nicholas Roberts, Jayant S. Vaidya, Michael Alvarado, Chris Brew-Graves, Jeffrey S Tobias, Elena Sperk, Douglas Brown, Max Bulsara, David McReady, Steffi Pigorsch, Jens Uwe Blohmer, Michael Baum, Richard A. Hoefer, Günther Gruber, Lorenzo Vinante, Michael Douek, Henrik Flyger, Marcus Niewald, Siobhan Laws, Pond R. Kelemen, Wojciech Polkowski
Publikováno v:
British Journal of Cancer
Background The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyse
Autor:
Pierre Zachee, David M. Ross, Lynda Foltz, Atanas Radinoff, Francesco Mannelli, Evren Zor, Francisco Cervantes, Francesco Passamonti, Heinz Gisslinger, Geralyn Gilotti, Haifa Kathrin Al-Ali, Francesca Palandri, Alexandr Myasnikov, Alessandro M. Vannucchi, Islam Sadek, Ranjan Tiwari, Norio Komatsu
Publikováno v:
Leukemia
Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) evaluated the efficacy and safety of a novel ruxolitinib dosing strategy with
Autor:
Vincent Cheung, Rosalin Cooper, Isar Nassiri, Anna Olsson-Brown, Robert A. Watson, Mark Coles, Umair Akbani, Mark R. Middleton, Chelsea A Taylor, Joseph J. Sacco, Weiyu Ye, Oliver Brain, Rubeta N Matin, Robert D Morgan, Miranda Payne, Benjamin P. Fairfax, Nicholas Coupe
Publikováno v:
British Journal of Cancer
BRITISH JOURNAL OF CANCER
BRITISH JOURNAL OF CANCER
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear. Methods Retrospecti
Autor:
Courtney D. DiNardo, Lewis R. Silverman, Charles Cai, Claudia D. Baldus, Isabelle Genvresse, Eleni Lagkadinou, Neil Palmisiano, Walter Fiedler, Alice S. Mims, Michael Jeffers, Markus Wagner, Ioannis Mantzaris, Alexander E. Perl, Gary Wilkinson, Bingyan Wu, Christine Rentzsch, Eunice S. Wang, Timothy S. Pardee, Sebastian Schwind, Stefan Kaulfuss, Michael Heuser, Alwin Krämer
Publikováno v:
Leukemia
The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses rang
Autor:
Daiki Ikarashi, Hidenori Mizugaki, Takashi Tsuyukubo, Asumi Sakaguchi, Renpei Kato, Shigekatsu Maekawa, Makiko Yamashita, Hiroko Onagi, Tetsuya Nakatsura, Shigehisa Kitano, Tamotsu Sugai, Takayuki Nakayama, Kazumasa Takenouchi, Yoichiro Kato, Wataru Obara
Publikováno v:
Br J Cancer
BACKGROUND: We examined the relationship between the tumour microenvironment and the clinical efficacy of neoadjuvant chemotherapy in patients with cT2-4aN0M0 bladder cancer using multiplex fluorescence immunohistochemistry. METHODS: The study retros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03eea905b1c9ebdc8e04f859abf3d050
https://europepmc.org/articles/PMC8854605/
https://europepmc.org/articles/PMC8854605/
Autor:
Kimberly S. Smythe, Darci J. Phillips, Robert H. Pierce, Salil S. Bhate, Yury Goltsev, Youn H. Kim, Magdalena Matusiak, Christian M. Schürch, Steven P. Fling, Garry P. Nolan, Martin A. Cheever, Janos Demeter, Graham L. Barlow, Sizun Jiang, Nirasha Ramchurren, Robert West, Michael S. Khodadoust, Belén Rivero Gutierrez
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically unmet need for predictive biomarkers of response. Herein, we perform C
Autor:
Patrick Eulitt, William Weir, Michele C. Hayward, Tracy L. Rose, Matthew I. Milowsky, Katrina A. McGinty, Michael V. Millburn, Mi Zhou, Yoichiro Shibata, Matthew E. Nielsen, Ashley H. Salazar, Gregory Mayhew, William Y. Kim, Joel R. Eisner, Angela B. Smith, Sara E. Wobker, Joshua M. Uronis, Michael Woods
Publikováno v:
Br J Cancer
Background FGFR3-altered urothelial cancer (UC) correlates with a non-T cell-inflamed phenotype and has therefore been postulated to be less responsive to immune checkpoint blockade (ICB). Preclinical work suggests FGFR3 signalling may suppress pathw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a067ed93f6f1a9fec850b6412c6c901
https://europepmc.org/articles/PMC8548561/
https://europepmc.org/articles/PMC8548561/
Autor:
Wenyang Huang, Hui Cheng, Shuang Xia, Wen Zhou, Junqiang Lv, Tao Cheng, Xuehan Mao, Weiwei Sui, Gang An, Chenxing Du, Shuhui Deng, Mu Hao, Xiaoke Ma, Jie Xu, Zhen Yu, Lanting Liu, Lugui Qiu, Xiaojing Wei
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Anaemia is the most common complication of myeloma and is associated with worse clinical outcomes. Although marrow replacement with myeloma cells is widely considered a mechanistic rationale for anaemia, the exact process has not been fully understoo
Autor:
Myung-Ju Ahn, Mi Soon Kim, Keunchil Park, Jin Seok Ahn, Kyoung Young Lee, Jiae Koh, Joon Young Hur, Bo Mi Ku, Se-Hoon Lee, Jong-Mu Sun, Jae Yeong Heo
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Antitumor immune responses induced by immune checkpoint inhibitors anti-PD-1 or anti-PD-L1 have been used as therapeutic strategies in advanced non-small cell lung cancer (NSCLC) patients over the last decade. Favorable antitumor activity to immune c
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 6, Pp 1-11 (2020)
Cell Death and Disease, Vol 11, Iss 6, Pp 1-11 (2020)
Heparan sulfate proteoglycan 2 (HSPG2), also known as perlecan, is a large multi-domain extracellular matrix proteoglycan, which contributes to the invasion, metastasis and angiogenesis of solid tumor. However, very little is known about the effect o